Parabilis Medicines, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Parabilis Medicines, Inc. | PBLS - NASDAQ |
$17.00-$19.00 |
$20.00 |
$33.35 | 33.5 million | 6/10/2026 |
| Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital |
Co-Manager(s): |
| Health Care |
Filing(s): Filed 2026-05-19 Terms Added 2026-06-04
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Parabilis Medicines, Inc., and our comprehensive analysis, click "Buy Market Research".
Parabilis Medicines, Inc. Quote & Chart - Click for current quote -
PBLS
About Parabilis Medicines, Inc. (adapted from Parabilis Medicines, Inc. prospectus):
They are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PBLS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2026 IPO Boutique. All Rights Reserved